Beyond Air (NASDAQ:XAIR) Releases Quarterly Earnings Results, Misses Expectations By $0.20 EPS

Beyond Air (NASDAQ:XAIR) released its earnings results on Thursday. The company reported ($11.00) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($10.80) by ($0.20), Zacks reports. The company had revenue of $1.77 million during the quarter, compared to analysts’ expectations of $1.93 million. Beyond Air had a negative net margin of 432.99% and a negative return on equity of 350.00%.

Here are the key takeaways from Beyond Air’s conference call:

• Second-quarter revenue was $1.8 million, essentially flat year over year and sequentially. Gross margin improved to 13%, marking the third consecutive quarter of positive gross profit, although the company still reported a $7.9 million net loss.
• Beyond Air raised $10 million upfront through financing with potential for up to an additional $20 million from warrant exercises, strengthening its ability to fund Gen 2 LungFit PH production, commercial preparations, and international expansion.
• The company said its Gen 2 LungFit PH submission remains on track for potential FDA approval in the second half of 2026, with audits and pilot builds underway. Management described FDA communication as strong but cautioned that timing remains subject to the agency’s review.
• Commercial momentum is building, including a new national group purchasing agreement that gives Beyond Air access to a substantial portion of U.S. hospitals, a pipeline that management says has doubled over the past five to six months, and distribution partnerships spanning more than 40 countries.
• Management reaffirmed 2026 revenue guidance of $8 million and 2027 guidance of $16 million to $18 million; the 2027 outlook includes potential Gen 2 LungFit PH revenue, while the 2026 forecast excludes any contribution from the new system.

Beyond Air Trading Up 14.4%

NASDAQ XAIR opened at $6.92 on Friday. The firm has a market capitalization of $4.98 million, a price-to-earnings ratio of -0.08 and a beta of 0.23. The company has a debt-to-equity ratio of 3.48, a quick ratio of 3.59 and a current ratio of 3.80. Beyond Air has a one year low of $5.02 and a one year high of $95.60. The company’s 50 day moving average price is $7.15 and its 200 day moving average price is $12.26.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Beyond Air in a report on Tuesday, July 21st. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $200.00.

Insider Transactions at Beyond Air

In other Beyond Air news, CEO Robert Scott Goodman acquired 34,722 shares of the company’s stock in a transaction dated Wednesday, July 29th. The stock was bought at an average price of $5.76 per share, with a total value of $199,998.72. Following the completion of the transaction, the chief executive officer directly owned 34,822 shares of the company’s stock, valued at approximately $200,574.72. The trade was a 34,722.00% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 9.99% of the stock is currently owned by corporate insiders.

Institutional Trading of Beyond Air

A number of institutional investors have recently added to or reduced their stakes in the business. Virtu Financial LLC purchased a new position in Beyond Air in the third quarter valued at about $48,000. Geode Capital Management LLC raised its holdings in shares of Beyond Air by 57.5% during the 4th quarter. Geode Capital Management LLC now owns 67,678 shares of the company’s stock valued at $49,000 after buying an additional 24,695 shares during the period. Osaic Holdings Inc. raised its holdings in shares of Beyond Air by 26.4% during the 2nd quarter. Osaic Holdings Inc. now owns 162,560 shares of the company’s stock valued at $29,000 after buying an additional 34,000 shares during the period. Finally, Alyeska Investment Group L.P. acquired a new position in Beyond Air during the 3rd quarter worth approximately $1,753,000. 31.50% of the stock is owned by hedge funds and other institutional investors.

Beyond Air Company Profile

Beyond Air, Inc is a clinical-stage medical technology company focused on the development and commercialization of inhaled nitric oxide (NO) therapy for pulmonary and respiratory diseases. The company’s proprietary LungFit® platform delivers pulsed, low-dose nitric oxide gas through compact, portable devices designed to support treatments in both inpatient and outpatient settings. Beyond Air’s approach leverages NO’s antimicrobial, vasodilatory and anti-inflammatory properties to address a range of unmet needs in respiratory medicine.

The company’s lead candidate, LungFit® PH, is under investigation for the treatment of pulmonary hypertension, with ongoing clinical studies assessing its impact on pulmonary arterial pressure and exercise capacity.